More insured people buying more medicine: the math is deceptively simple, but drug companies say the numbers don't necessarily add up

Guardedly optimistic: the outlook for the biopharma sector in New Jersey and the major metropolitan area.

New Jersey Department of Labor focuses on folks who lost jobs in latest round of consolidations and relocations

Downsizing, consolidation, relocation take toll on New Jersey's pharmaceutical sector

Allergan agrees to open R&D center in NJ, raising questions about what really attracts pharmaceutical companies to the state.

Realigning a high-tech incentive program so that it only applies to biotechs could give New Jersey more of what it needs: high-quality, high-paying jobs.

The loss of some 1,400 jobs in Kenilworth will touch restaurateurs and real estate agents, and is emblematic of changes in the pharmaceutical sector throughout ...

Academia and industry are just starting to work together in the Garden State. Can each deliver what the other needs to thrive?

Finding enough cash to conduct their operations is job No. 1 for New Jersey's numerous biotechs.

Cutbacks, mergers, and layoffs; intense competition from lower-cost generics; and fierce rivalry from other regions make for a troubled prognosis for NJ’s big drug makers.